CHATSWORTH, Calif., April 6, 2011 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, and a provider of high value personalized diagnostics testing services through its CLIA certified molecular diagnostics laboratory, announced today that, following recent 510(k) market clearance on March 24 from the U.S. Food and Drug Administration (FDA), it has immediately commenced the U.S. commercial activities with the shipment in March of its iChem®Velocity™ Automated Urine Chemistry Analyzers in combination with its iRICELL® Urinalysis Workstations to three U.S. hospitals.
